If you are suffering from side effects of the drug Xeljanz, you may want to file a Xeljanz lawsuit against the manufacturer. The drug is known to increase the risk of cardiovascular problems and blood clots in the lungs. It’s also linked to cancer. If you have used the drug, you may wish to consult with a qualified attorney to file a lawsuit.
Xeljanz increases the risk of heart problems
The FDA has warned that Xeljanz can increase the risk of blood clots and heart problems, which can lead to heart attacks, strokes, or pulmonary embolism. Although the drug is approved for treating many conditions, such as ulcerative colitis and moderate-to-severe rheumatoid arthritis, it has now come under scrutiny because of an increase in heart problems.
Until recently, the makers of Xeljanz didn’t warn about the potential risk of cardiovascular problems. Their product monographs did not mention that the drug was associated with an increased risk of pulmonary embolism or blood clots. However, in 2012, Health Canada forced Pfizer to add a precautionary note advising patients with heart disease to take note of the increased risk of cardiovascular problems.
After the study was finished, the FDA issued a new safety alert for Xeljanz, noting that it increased the risk of heart problems and cancer in patients taking the drug. The new safety warnings were based on results from a large randomized clinical trial funded by the drug’s maker. The study found that Xeljanz users had a higher risk of heart problems and pulmonary embolism than those taking placebo. Moreover, it was also associated with an increased risk of blood clots and serious infections.
Xeljanz has also been associated with an increased risk of cancer in kidney transplant recipients and an increased risk of infections in people with compromised immune systems. In addition, it has also been linked to an increased risk of death in patients with certain diseases such as rheumatoid arthritis and heart disease. Moreover, Xeljanz increases the risk for cardiovascular problems in patients with high cholesterol and obesity.
Xeljanz increases the risk of cancer
The use of Xeljanz is associated with an increased risk of developing cancer, especially among people who have recently undergone kidney transplant surgery. It can also increase the risk of infections, particularly those caused by the Epstein-Barr virus. Some people are also at higher risk for heart disease, particularly those who have high cholesterol or high blood pressure.
Because of this increased risk, the FDA has limited the use of Xeljanz for ulcerative colitis patients. In February, the agency issued a safety communication, alerting the public that Xeljanz increased the risk of serious cardiovascular events, including cancer. The FDA found that both lower and higher doses of Xeljanz significantly increased the risk of cancer and heart problems.
The new study raises concerns about Xeljanz and other JAK inhibitors. It is important to note that the authors of the study are Pfizer employees and the company funded the study. While the study’s results have to be further evaluated, patients who are taking Xeljanz should make note of the findings.
Xeljanz also suppresses the immune system, which leaves patients susceptible to infections. In one study, almost 20% of people taking the drug reported getting an infection or developing an infection. These infections ranged from urinary tract infections to serious infections, such as pneumonia, diverticulitis, and appendicitis. It can also reactivate latent infections and trigger opportunistic infections.
Xeljanz increases the risk of blood clots in the lungs
Xeljanz is a prescription drug approved for the treatment of chronic obstructive pulmonary disease (COPD). This medication increases the risk of blood clots forming in the lungs, a side effect that has caused the drug’s label to be changed. The drug’s manufacturers failed to include a warning on the label. However, the FDA and a group of scientists have now made changes to the medication.
A safety alert issued by the Food and Drug Administration in February 2019 warned that Xeljanz increases the risk for DVT and PE. The drug maker, Pfizer, has been ordered to update its prescribing information to reflect the increased risk. A DVT is a blood clot that forms in a vein.
Xeljanz has been associated with a high risk of blood clots in the lung, and it may increase the risk of heart attack, stroke, and cancer. It was originally approved for treating moderate to severe rheumatoid arthritis, but the FDA has since issued a warning regarding the drug’s increased risk for blood clots.
Xeljanz is a prescription drug that has caused a large number of people to develop blood clots in the lungs. These clots can have devastating consequences, including the development of pulmonary embolism. This is why the drug maker was ordered by the FDA to update its warning label.
